50 results
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
26 Oct 22
Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
7:48am
the company’s and Celgene’s business and operations, including with respect to human capital management, portfolio rationalization, finance and accounting
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
27 Jul 22
Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
7:44am
the company’s and Celgene’s business and operations, including with respect to human capital management, portfolio rationalization, finance
8-K
EX-99.1
4534c
29 Apr 22
Bristol Myers Squibb Reports First Quarter Financial Results for 2022
7:42am
DEFA14A
i5eosz6c
20 Apr 22
Additional proxy soliciting materials
4:30pm
8-K
EX-99.2
2scmi1g4
3 Mar 22
Upsizing and Early Settlement of Tender Offers
4:16pm
8-K
EX-99.1
ykfb6tp1khgz9wh
3 Mar 22
Upsizing and Early Settlement of Tender Offers
4:16pm
424B5
v36zbza lrmm
17 Feb 22
Prospectus supplement for primary offering
4:47pm
8-K
EX-99.1
ih76 a24q
15 Feb 22
Bristol Myers Squibb Announces Tender Offers
9:16am
424B3
l2oo27cl 50
15 Feb 22
Prospectus supplement
9:13am
8-K
EX-99.1
a3y3a2 ssn1i148bm
4 Feb 22
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
7:50am
8-K
EX-99.1
ju251esx
27 Oct 21
Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
9:46am
8-K
EX-99.1
uysfdauerpa ba1u
28 Jul 21
Bristol Myers Squibb Reports Second Quarter Financial Results for 2021
7:33am
8-K
EX-99.1
ylkmwxskqnk
29 Apr 21
Bristol Myers Squibb Reports First Quarter Financial Results for 2021
8:38am
DEFA14A
8yw 5qbd5
19 Apr 21
Additional proxy soliciting materials
7:41am